Crossmark

Final Results of ERBIMOX: A Randomized Phase II Study of Modified FOLFOX7 With or Without Cetuximab as First-Line Treatment for KRAS Wild-type Metastatic Colorectal Cancer

Crossref DOI link: https://doi.org/10.1007/s12029-025-01260-6

Published Online: 2025-06-27

Published Print: 2025-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Potthoff, Karin

Marschner, Norbert

Müller, Lothar

Sahm, Stephan

Lerchenmüller, Christian

Depenbusch, Reinhard

Boller, Emil

Niemeier, Beate

Zirrgiebel, Ute

Tesch, Hans
License Information

Text and Data Mining valid from 2025-06-27

Version of Record valid from 2025-06-27
More Information

Article History

Accepted: 14 June 2025

First Online: 27 June 2025

Declarations

:

: The authors declare no competing interests concerning the topic of this publication. Outside of the published work, the institutions of LM, SS, CL, RD and HT received remuneration for the documentation of patient data; NM declares stock ownership and upper management responsibility (iOMEDICO); SS declares stock ownership (Merck); HT declares stock ownership (CHOP GmbH, VISION MED GmbH, Care and Coach GmbH).

Document is current

Any future updates will be listed below